Quris is a multidisciplinary team tackling some of the world’s greatest challenges in the drug safety domain. We are building the world’s first Bio-AI, a ‘patient-of-a-chip’ clinical prediction platform. The platform generates millions of interactions between miniaturized 3D human organs and known/potential drugs. Our multimodal deep learning is training to predict whether a new drug candidate will work safely on the human body.
Quris AI
contact@quris.ai
הנציב 6 תל אביב
0584090490
https://www.quris.ai/
Quris uniquely combines the power of cutting-edge ML together with patients-on-chip technology, to better predict drug safety. How does it work? While science and technology are complex, their essence is a simple, three-tiered process:
- Generate millions of interactions between known drugs (safe drugs and toxic ones) and patients-on-chip (miniaturized interconnected human organs on a chip).
- Train the AI model, based on the proprietary multi-modality labeled data. Including microscopy images and proprietary nano-sensing.
- Predict whether a new drug candidate will be safe for the human body, and for whom.
Based in Boston and Tel-Aviv, Quris is led by a team of track-record pioneers in the fields of machine-learning, statistics, biology, software, genomics, engineering, and med-tech – all with a strong track record of success, including Moderna’s co-founder Langer, Nobel laureate Ciechanover, and former Pfizer CEO McKinnell. The founders authored 48 patents, led two FDA-approved products, and had multiple successful Life-Sci exits (M&A, NASDAQ IPO).